Many of the most important proteins for understanding human disease exist at extremely low concentrations, often far below the detection limits of conventional immunoassays or mass spectrometry. These signaling proteins can read out early pathological states, subtle immune dysregulation, and treatment response or resistance – so missing them misses critical biology to inform drug development.
As a Certified Service Provider for Alamar Biosciences’ NULISA cytokine release assays and panels, Sapient enables ultra-sensitive detection of hard-to-assay cytokines, chemokines, and neuroinflammatory mediators in biofluid samples.
The NULISA platform uses a proprietary sequential immunocomplex capture and release technique to improve the sensitivity of traditional proximity ligation assays by over a thousand-fold to attomolar levels – allowing for highly quantitative measures of low-abundance proteins that are not amenable to mass spectrometry measure.
Run on the ARGO™ HT System, housed on-site in Sapient’s lab, NULISA panels and assays enable ultra‑sensitive measurement of key cytokines and chemokines that are difficult to detect using other analytical tools. This precise quantification also allows us to cross‑validate proteins identified through our mass‑spectrometry–based discovery proteomics screenings.
Attomolar-level of detection (fg/ml)
Up to 12 logs of dynamic range
Flexible multiplex chemistry to quantify 1 or hundreds of targets in a single experiment
Contextualization of findings in DynamiQ™
Multi-omics integration with other omics workflows applied to the same samples
The result? Robust findings that can be rapidly strengthened with additional mechanistic evidence.
This Nature Communications paper demonstrates the exceptional performance of the NUcleic acid Linked Immuno-Sandwich Assay (NULISA™) in detecting biologically important low-abundance biomarkers.
As the only NULISA panel provider with a population-scale molecular-clinical database, Sapient offers the unique ability to both analyze your samples and validate the findings in independent real-world cohorts – as well as to layer additional omics data to orthogonally validate and extend discoveries.
Developed to cover 250+ biomarkers of inflammation and immune response, including with absolute quantitation.
For multiplexed analyses of 220+ biomarkers of neurodegenerative disease, including neuro-specific proteins.
Designed specifically for mouse and murine experiments, profiling 120 immune- and neurology-related proteins.
Low- and single-plex assays for absolute quantitation of key proteins implicated in neurodegenerative diseases.
Sapient enables you to validate what others can only hypothesize by analyzing your NULISA panel results within our large-scale reference dataset, DynamiQ.
This molecular-clinical database of >67,000 pre-characterized human plasma samples can be used to biologically contextualize your biomarker in independent cohorts and to build human-relevant evidence to confirm preclinical discoveries.
We can also integrate omics datasets – including from genomics, RNAseq, single-cell sequencing, and spatial profiling – to further improve mechanistic understanding.
Tap our deep expertise in assay development and NULISA technologies to obtain robust measures for difficult-to-assay cytokines, chemokines, and inflammatory mediators.
"*" indicates required fields
